Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods and compositions for treating retina-associated disease using ccr3-inhibitors

A retinal and disease-related technology, applied in drug combinations, sensory diseases, allergic diseases, etc., can solve problems such as failure to develop CCR3 antagonists

Inactive Publication Date: 2020-01-03
ALKAHEST INC
View PDF8 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] Despite this promise, the industry has failed to develop CCR3 antagonists for the treatment of retina-related diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for treating retina-associated disease using ccr3-inhibitors
  • Methods and compositions for treating retina-associated disease using ccr3-inhibitors
  • Methods and compositions for treating retina-associated disease using ccr3-inhibitors

Examples

Experimental program
Comparison scheme
Effect test

example

[0661] a. Pharmaceutical preparations

[0662] The pharmaceutical composition administered to subjects suffering from retinal-related diseases can use U.S. Patent Application Publication Nos. 2013 / 0266646, 2016 / 0081998, U.S. Patent Nos. 8,278,302, 8,653,075, RE45323, 8,742,115, and The synthesis, preparation and formulation of the examples disclosed in Nos. 9,233,950 and 8,680,280, the entire contents of the patents are incorporated herein by reference. In addition, the pharmaceutical composition can be prepared as described in the following examples:

[0663] 1. Tablet formulation-wet granulation

[0664] Copovidone is dissolved in ethanol at ambient temperature to produce a granulating liquid. The active CCR3 antagonist ingredients, lactose and part of crospovidone are mixed in a suitable mixer to produce a premix. The premix is ​​wetted with a granulation liquid and then granulated. Optionally, the wet granules are sieved through a sieve with a mesh size of 1.6-3.0 mm. The gr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

Methods of improving visual endpoints related to retina-associated disease with CCR3 modulating agents are provided. An example of such an endpoint is visual acuity. Retina-associated diseases upon which visual acuity and other visual endpoints may be improved include retinopathy of prematurity, age-related macular degeneration, central retinal vein occlusion, and diabetic retinopathy.

Description

[0001] Cross references to related applications [0002] This application claims priority from U.S. Patent Application No. 62 / 482,134 filed on April 5, 2017, which is incorporated herein by reference. Technical field [0003] The present invention relates to materials and methods for improving the visual acuity of individuals in need. Background technique [0004] Among a variety of retinal-related diseases, there are those diseases that manifest themselves early in life and those that manifest themselves in relation to aging. An example of the former type of disease is retinopathy of prematurity (ROP). Examples of age-related retinal-related diseases include: age-related macular degeneration (AMD), which is the most common macular degenerative disease; central retinal vein occlusion (CRVO), and diabetic retinopathy. Untreated retinal-related diseases can cause legal blindness. [0005] AMD is the leading cause of irreversible blindness in people aged 50 or over in developed countr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4523A61K31/454A61P37/00A61P31/00A61K31/4545A61K9/00
CPCA61K31/4545A61K45/06A61P27/02A61P31/00A61P37/00A61K2300/00A61K9/2059A61K9/2054A61K9/282A61K9/2853A61K9/145A61K31/5377A61K9/2866A61K9/2813A61K9/143A61K9/284A61K9/2018C07B2200/13A61K9/2027
Inventor L.科拉迪尼S.杰克逊K.尼科利奇
Owner ALKAHEST INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com